HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.